亚辉龙公告称，预计2025年度归属于母公司所有者的净利润为2000万元至3000万元，同比减少90.05% 至93.37%；扣非净利润6500万元至8500万元，同比减少70.42%至77.38%。业绩下降主因行业政策致国 内市场需求减少、营收和毛利率下降，交易性金融资产亏损及计提资产减值准备。不过，海外业务稳定 增长，术前八项全系列试剂IVDR CE认证全覆盖。产品研发成果丰硕，国内化学发光产品菜单扩至180 项，多项产品获认证或授权。 ...

Core Insights - Shenzhen YHLO Biotech Co., Ltd. has made significant strides in the field of industry-academia-research collaboration by establishing two joint laboratories with Hong Kong University of Science and Technology (Shenzhen) and Shenzhen Technology University, focusing on neurological diagnosis and intelligent diagnostics [2][3] Group 1: Joint Laboratories - The "Neurodiagnosis Joint Laboratory" will focus on major neurodegenerative diseases such as Alzheimer's and Parkinson's, conducting systematic research on disease biomarkers, diagnostic technology development, and key equipment research [3] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" will concentrate on AI image recognition systems, microfluidic detection platforms, and the exploration of new biomarkers, aiming to develop key technologies in intelligent diagnostics and precision medicine [3] Group 2: Strategic Goals - Both laboratories aim to convert core research outcomes into marketable products within 3 to 5 years while cultivating innovative and practical talent [3] - The establishment of these laboratories reflects YHLO's commitment to a clinical demand-oriented and industry transformation-focused collaboration logic [3][4] Group 3: Long-term Collaboration - YHLO's Chairman and CEO emphasized that the collaboration with universities is not just about project alignment but also about systematic and institutional long-term cooperation [4] - The joint laboratories are expected to facilitate a full chain from frontier research to technology development, product transformation, and clinical application, ultimately benefiting patients [4][5]

Group 1 - The core viewpoint of the news is that Aihua Long has established two joint laboratories with universities in Shenzhen, focusing on neurological diagnosis and intelligent diagnosis, which signifies the company's commitment to advancing its capabilities in the in vitro diagnostics and life health sectors [1][2][3] Group 2 - The "Neurodiagnosis Joint Laboratory" with the Chinese University of Hong Kong (Shenzhen) will focus on major neurodegenerative diseases such as Alzheimer's and Parkinson's, conducting systematic research on disease biomarkers, diagnostic technology, and key equipment development [1] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" with Shenzhen Technology University will concentrate on AI image recognition systems, microfluidic detection platforms, and the development of new biological markers, aiming to convert core R&D results into marketable products within 3 to 5 years [2] - Aihua Long's collaboration with these universities reflects a strategy of integrating clinical needs with industrial transformation, emphasizing a systematic and institutional long-term cooperation model [2][3] - The establishment of these laboratories is expected to enhance Aihua Long's product line and technical reserves, contributing to the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area [3] - The company aims to create a comprehensive innovation ecosystem in the health industry through the integration of research, technology development, product transformation, and clinical application [2][3]

Group 1 - On January 19, Shenzhen Aihuilong Biotechnology Co., Ltd. (Aihuilong, 688575.SH) established two joint laboratories with Hong Kong University of Science and Technology (Shenzhen) and Shenzhen Technology University, focusing on neurological disease diagnosis and intelligent diagnosis and precision medicine [1][2] - The "Neurodiagnosis Joint Laboratory" will focus on early diagnosis and treatment of neurological diseases, particularly Alzheimer's and Parkinson's diseases, addressing the challenges in the diagnosis of neurological disorders [4][8] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" aims to develop AI image recognition systems, microfluidic detection platforms, and new biomarkers, leveraging the strengths of both universities and Aihuilong's market experience [5][7] Group 2 - Aihuilong's collaboration with two universities reflects its commitment to integrating clinical needs with industrial transformation, emphasizing a systematic and long-term partnership approach [8] - The establishment of these laboratories is expected to enhance Aihuilong's product line and technical reserves, contributing to the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area [8] - The joint laboratories will facilitate a comprehensive approach from cutting-edge research to clinical application, aiming to create an innovative ecosystem in the health industry [8]

Group 1 - The core stock price of Aihuilong (688575) closed at 15.15 yuan on January 16, 2026, down by 1.5% with a turnover rate of 1.33% and a trading volume of 75,900 hands, resulting in a transaction amount of 115 million yuan [1][2] - On January 16, the net outflow of main funds was 17.79 million yuan, indicating a cautious attitude from major investors [2] - Retail investors showed a net inflow of 2.18 million yuan, suggesting some level of interest from smaller investors [1] Group 2 - Aihuilong plans to conduct foreign exchange hedging business with a maximum amount not exceeding 600 million yuan, aimed at mitigating exchange rate risks [1][2] - The expected upper limit for the margin and premium for the transactions is set at 30 million yuan, funded by the company's own resources [1] - The business will be valid for 12 months from the date of approval by the board of directors and the funds within the limit can be reused [1]

Core Viewpoint - The recent surge in A-share market activity has led to regulatory scrutiny of several companies involved in popular concepts like commercial aerospace, brain-computer interfaces, and artificial intelligence due to issues with information disclosure and risk warnings [1][2]. Group 1: Companies Under Scrutiny - Five companies, including Hangxiao Steel Structure, Electric Science Digital, Yahui Long, Yingjixin, and Tianpu Co., have received warning letters or are under investigation for misleading disclosures related to trending market concepts [1][2]. - Tianpu Co. experienced a significant stock price increase of 16 times by 2025, raising concerns about its information disclosure practices [1]. Group 2: Specific Company Issues - Hangxiao Steel Structure failed to accurately disclose the impact of its involvement in a commercial aerospace project, with the contract amount accounting for less than 1% of its 2024 audited revenue [2]. - Electric Science Digital reported that its satellite communication and AI products had minimal sales impact, with 2025 orders amounting to approximately 0.1% of overall business [3]. - Yahui Long's announcement regarding a strategic partnership in brain-computer interfaces lacked clarity on the technical capabilities of its partner, leading to regulatory warnings [4][5]. - Yingjixin's disclosures about its brain-computer interface chip were found to be misleading regarding the product's market readiness and sales impact [6]. - Tianpu Co. did not clarify its connection to artificial intelligence despite establishing a subsidiary focused on related technologies, leading to regulatory action [7][8]. Group 3: Historical Context and Trends - Several of the companies involved have a history of information disclosure issues, with Hangxiao Steel Structure being notably linked to a major insider trading case [12][13]. - The information disclosure ratings of these companies have declined significantly, with Hangxiao Steel Structure dropping from B to C, Electric Science Digital from A to B, and Tianpu Co. from B to D [12].

Core Viewpoint - Aihuilong (688575) has experienced a decline in stock price, closing at 15.15 yuan, down 3.13% from the previous week, with a total market capitalization of 8.657 billion yuan [1] Company Announcements - Aihuilong plans to engage in foreign exchange hedging activities with a limit not exceeding 600 million yuan or equivalent foreign currency, aimed at mitigating exchange rate risks [1] - The expected maximum transaction margin and premium for this hedging activity is set at 30 million yuan or equivalent foreign currency, funded by the company's own resources [1] - The business will be valid for 12 months from the date of approval by the board of directors and the funds within the limit can be reused [1] - The board of directors has approved this matter in its ninth meeting of the fourth session, and it does not require submission to the shareholders' meeting for approval [1]

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. plans to conduct foreign exchange hedging business with a maximum amount of RMB 600 million or equivalent foreign currency to mitigate exchange rate risks [2][3]. Group 1: Overview of Foreign Exchange Hedging Business - The purpose of the foreign exchange hedging business is to manage exchange rate and interest rate risks arising from the company's import and export operations, primarily involving foreign currency settlements [3]. - The hedging activities will be based on normal production and operations, aiming to avoid speculative and arbitrage trading [3][4]. Group 2: Transaction Amount and Funding - The company intends to use no more than RMB 600 million or equivalent foreign currency from its own funds for the hedging activities, with a maximum of RMB 30 million or equivalent foreign currency allocated for transaction margins and premiums [2][4]. - The funding will come from the company's own resources and will not involve raised funds [5]. Group 3: Transaction Methods and Approval - The hedging tools may include forward foreign exchange contracts, foreign exchange swaps, foreign exchange options, foreign exchange interest rate swaps, foreign exchange futures, and currency swaps [5]. - The board of directors approved the hedging proposal on January 15, 2026, and this matter does not require submission to the shareholders' meeting [8]. Group 4: Risk Analysis - The foreign exchange hedging business aims to effectively manage foreign currency assets and mitigate risks from exchange rate fluctuations, although it still carries certain risks such as market risk, credit risk, and liquidity risk [9][10]. - The company will not engage in speculative trading, focusing instead on risk management [11]. Group 5: Impact on the Company and Accounting Treatment - The foreign exchange hedging activities are intended to mitigate risks from exchange rate fluctuations, and related hedging instruments will be treated as trading financial assets/liabilities according to accounting standards [13].

Core Viewpoint - The company, Aihuilong (688575), has announced plans to engage in foreign exchange hedging activities to mitigate currency risk, with a funding limit of up to 600 million RMB or equivalent foreign currency [1] Group 1: Stock Performance - As of January 16, 2026, Aihuilong's stock closed at 15.15 RMB, down 1.5% from the previous trading day [1] - The stock opened at 15.39 RMB, reached a high of 15.53 RMB, and a low of 15.00 RMB, with a trading volume of 1.15 billion RMB and a turnover rate of 1.33% [1] Group 2: Business Announcement - Aihuilong and its subsidiaries plan to conduct foreign exchange hedging with a maximum funding limit of 600 million RMB or equivalent foreign currency [1] - The expected maximum margin and premium for the transactions will be 30 million RMB or equivalent foreign currency, funded from the company's own resources [1] - The business will be valid for 12 months from the date of approval by the board of directors and the funds within the limit can be reused [1] - The board has approved this matter in its ninth meeting, and it does not require submission to the shareholders' meeting [1] - The purpose of this business is to avoid and prevent exchange rate risks, without engaging in speculation or arbitrage [1]

证券代码：688575 证券简称：亚辉龙 公告编号：2026-005 深圳市亚辉龙生物科技股份有限公司 关于开展外汇套期保值业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"或"亚辉龙"）及 其子公司拟进行外汇套期保值业务资金额度不超过人民币60,000万元或等值外 币，预计动用的交易保证金和权利金上限（包括为交易而提供的担保物价值、预 计占用的金融机构授信额度、为应急措施所预留的保证金等）为3,000万元或等 值外币。资金来源为自有资金，不涉及募集资金。上述额度有效期为自公司董事 会审议通过之日起12个月内，在上述额度范围内，资金可循环滚动使用。 公司的套期保值业务以正常生产经营为基础，以规避和防范汇率风险为 目的，不进行单纯以营利为目的的投机和套利交易。 公司于2026年1月15日召开了第四届董事会第九次会议，审议通过了《关 于开展外汇套期保值业务的议案》，本次外汇套期保值业务事项无需提交公司股 东大会审议。 特别风险提示：公司开展外汇套期保值 ...